Skip to main content
. 2017 Mar 22;21(1):1–5. doi: 10.5114/wo.2017.66651

Table 1.

Response rate (RR) and progression-free survival (PFS) in patients with normal and elevated serum lactate dehydrogenase (LDH) in patients treated in CheckMate 066, 067, 069 studies

Nivolumab + ipilimumab Nivolumab Ipilimumab
RR
LDH ≤ ULN
LDH > ULN
LDH > 2 × ULN

65%
45%
33%

51%
31%
17%

23%
10%
0%
PFS
LDH ≤ ULN
LDH > ULN
LDH > 2 × ULN

NR
5.2 months
2.6 months

11.3 months
2.7 months
2.1 months

4.1 months
2.6 months
2.3 months